A prescription is no longer the finish line for an infused specialty therapy. Increasingly, where a patient can receive treatment determines whether therapy starts smoothly, gets delayed, or is abandoned. Payer policies, provider capacity, costs, and patient needs can all influence that destination. As a result, specialty pharma brands increasingly need a marketing strategy built around changing sites of care. The commercial challenge is shifting from simply winning the prescription to helping patients navigate the path from prescription to an appropriate infusion chair.
Table of Contents
- Why site of care is becoming a commercial issue
- How payer-directed care changes the patient journey
- Building a site-of-care strategy
- Turning patient support into an access advantage
- Conclusion
- FAQs
Why Site of Care Is Becoming a Specialty Pharma Battleground
Specialty infusion once centered heavily on hospital outpatient departments and established health system infusion centers. However, the landscape now includes physician offices, independent ambulatory infusion centers, infusion suites, specialty pharmacies, and home infusion.
Payer pressure is helping accelerate this change. Cencora notes that patient and payer preferences are moving care toward lower-cost, non-acute settings, including patients’ homes. It also warns that site-of-care shifts can create care gaps when health systems are not prepared for them.
For pharma brand teams, that creates a new commercial reality. The treatment experience can vary substantially depending on where a patient receives therapy. Moreover, authorization requirements, referral processes, drug acquisition models, staffing, and scheduling can differ across settings.
Therefore, brand teams need to understand more than prescribing behavior. They must understand the local infusion ecosystem surrounding the prescription.
That means site-of-care planning is increasingly part of the market access strategy, not just the marketing plan. Marketing cannot override payer policies or clinical decisions. Yet it can make transitions easier by providing relevant education, support resources, and clear pathways for stakeholders navigating those changes.
Payer-Directed Infusion Can Create Patient Journey Friction
Imagine a physician who recommends an infused specialty drug at the hospital where the patient normally receives care. The patient expects treatment to begin there. Then coverage requirements point the patient toward another eligible setting.
That change may sound simple on paper. In practice, it can introduce another referral, benefit verification, records transfer, scheduling process, and unfamiliar care team.
Patients may also have practical questions. Is the new center nearby? Will the same clinician oversee treatment? What will the therapy cost? Is home infusion appropriate? Who should the patient call when something goes wrong?
Clinical considerations remain central to these decisions. For example, an American Journal of Managed Care review of immunoglobulin therapy notes that site selection can involve medical history, comorbidities, travel ability, home environment, payer restrictions, financial burden, and patient preference.
Consequently, a site-of-care change is not merely a reimbursement event. It can become a patient experience event.
Brand teams should map these transition points before problems emerge. Furthermore, messaging should acknowledge that providers, patients, payers, specialty pharmacies, and infusion organizations may each see a different part of the journey.
Building a Site-of-Care Strategy Around the Treatment Ecosystem
An effective site-of-care strategy starts with understanding the treatment ecosystem. Brands should know where therapy can be administered, which sites commonly serve the target population, and where access barriers are likely to emerge.
Next, communication should reflect the needs of each stakeholder. Prescribers may need clear information about administration requirements and patient support. Meanwhile, infusion providers may need appropriate product education and operational resources. Patients need simple explanations of what happens next and where they can turn for support.
The strategy should also account for regional differences. Payer policies and infusion capacity can vary across markets. Therefore, a single national communication model may overlook important local barriers.
Brand managers can also connect site-of-care planning with broader specialty pharmacy marketing strategies. Specialty pharmacies increasingly participate in onboarding, affordability discussions, education, and ongoing patient engagement.
Similarly, Centers of Excellence can influence referrals and treatment patterns beyond their immediate geography. Understanding these networks can help marketers identify where education and access resources may have the greatest impact. Pharma Marketing Network’s coverage of Center of Excellence marketing offers additional context for this ecosystem-based approach.
The objective is not to promote one care setting as universally better. Instead, marketing should support informed navigation toward clinically appropriate, covered, and practical options.
Turn Patient Support Into a Site-of-Care Advantage
Patient support programs become especially valuable when the treatment location changes unexpectedly. A strong program can help patients understand coverage requirements, locate available resources, and navigate the administrative steps surrounding treatment initiation.
Therefore, hub services should be designed with site-of-care transitions in mind. Benefit verification, reimbursement support, educational materials, and communication workflows should connect rather than operate as isolated functions.
Speed matters as well. Every extra handoff can create another opportunity for confusion or delay. Consequently, brand teams should examine where patients disappear between prescription, authorization, referral, scheduling, and administration.
Digital tools can support that process when used carefully. For example, relevant reminders and status communications may help patients understand their next step. Provider-facing resources can also make support services easier to find at the moment they are needed.
This approach reflects a broader shift in how pharma brands design patient support programs. Support programs increasingly contribute to engagement and therapy persistence rather than serving only as reimbursement hubs.
Most importantly, marketers should measure more than impressions and clicks. Site-of-care programs can also examine referral completion, time to treatment, support utilization, and points of access friction while respecting applicable privacy and regulatory requirements.
Conclusion
The infusion chair has become an important part of the specialty pharma marketplace. Payers are applying site-of-care policies, alternate infusion settings are expanding, and patients may need to navigate several organizations before treatment begins.
For brand managers, that means awareness alone is not enough. A successful strategy for navigating different sites of care connects provider education, patient support, market access insights, and stakeholder communication around the real treatment journey.
The brands that understand these pathways can identify friction earlier and provide more useful support. Ultimately, winning the market is not simply about influencing the prescription. It is about helping ensure that an appropriate prescription can successfully become treatment.
FAQs
What is a site of care marketing strategy?
It is a coordinated approach that considers where specialty treatment is administered and how those settings affect education, access, patient support, and stakeholder communication.
Why are site-of-care policies important for specialty pharma?
They can influence where covered therapies are administered. Therefore, they may affect referrals, scheduling, patient experience, and the steps required to begin or continue treatment.
How can pharma marketers reduce site-of-care friction?
Teams can map treatment pathways, develop stakeholder-specific education, connect patients with support resources, and identify common breakdowns between authorization, referral, and treatment.
Does site-of-care marketing mean promoting home infusion?
No. The appropriate setting depends on clinical needs, coverage, available services, and individual circumstances. Marketing should support navigation and education rather than assume one setting is right for every patient.
What should brands measure in their site-of-care programs?
Useful measures can include time to treatment, referral completion, support program engagement, access barriers, and therapy initiation patterns. These measures can reveal where the patient journey needs additional support.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
